AGDas | ||||
---|---|---|---|---|
N | Mean (SD) mm | βa mm | 95% CI | |
No antifungal medicine use (reference) | 723 | 36.1 (5.7) | Reference | |
Vaginal tabletsb | 21 | 35.0 (7.2) | −1.9 | (−4.3; 0.5) |
Only vaginal tabletsc | 11 | 33.5 (7.5) | −3.0 | (−6.3; 0.3) |
Vaginal tablets in combination with creamc | 10 | 36.7 (6.8) | −0.7 | (−4.1; 2.8) |
Vaginal tablets in masculinisation programming windowd | 11 | 35.0 (8.1) | −2.2 | (−5.5; 1.1) |
Vaginal tablets outside the masculinisation programming windowd | 10 | 35.0 (6.4) | −1.6 | (−5.0; 1.9) |
Vaginal creamb only | 23 | 35.9 (6.7) | 0.1 | (−2.3; 2.4) |
Fluconazole oral tablets | 4 | 28.7 (4.2)e | −6.4e | (−11.9; −0.9)e |
Use of antifungal medicine but type not specified | 39 | 35.5 (6.5) | −0.9 | (−2.7; 0.9) |